Armata Pharmaceuticals Azioni (AMEX: ARMP)

Ultime notizie per Armata Pharmaceuticals (AMEX:ARMP) Azioni

Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals Inc

Shares of Amplify Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) rose sharply in today's pre-market after the company announced its termination of the previously announced merger agreement <a href="https://www.benzinga.com/quote/AMPY">with Juniper Capital</a>.
Amplify Energy shares jumped 15.5% to $3.11 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 47% to $0.0714 in pre-market trading after gaining around 25% on Friday.</li>
<li>Xunlei Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) surged 17.8% to $4.57 in pre-market trading after falling 5% on Friday.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) surged 15.1% to $7.92 in pre-market trading.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 13.1% to $5.70 in pre-market trading.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) gained 12.4% to $1.18 in pre-market trading. Faraday Future received powerful endorsements from California leaders backing FX brand, Bridge strategy, and YT Jia&#8217;s co-CEO appointment.</li>
<li>CPI Aerostructures, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVU#NYSE">CVU</a>) jumped 12.4% to $3.72 in pre-market trading.</li>
<li>Safe Bulkers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) rose 10.3% to $3.74 in pre-market trading a.</li>
<li>UMH Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>) gained 9.8% to $19.19 in pre-market trading.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares jumped 8.8% to $3.84 in pre-market trading after jumping 21% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 39.1% to $0.0790 in pre-market trading. Spruce Biosciences approved a plan to implement a workforce reduction of 55% on April 21, 2025, effective immediately.</li>
<li>Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares dipped 18.9% to $0.2640 in pre-market trading. Baijiayun shares surged around 75% on Friday after the company announced a multi-year investment plan to build a new ecosystem for autism rehabilitation.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) declined 17.6% to $5.26 in pre-market trading.</li>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares tumbled 15.9% to $1.27 in pre-market trading. Odyssey Marine Exploration shares surged 77% on Friday amid President Trump&#8217;s plans to advance the deep sea mining industry.</li>
<li>Jiuzi Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) fell 14.6% to $2.53 in pre-market trading after gaining 25% on Friday.</li>
<li>Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) fell 14.4% to $3.51 in pre-market trading. Citigroup, on Friday, maintained a Buy rating on Health Catalyst and lowered the price target to $6.5.</li>
<li>Viemed Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) shares fell 13.5% to $6.12 in pre-market trading. Viemed Healthcare will host its first quarter earnings conference call on Thursday, May 8.</li>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) dipped 13.2% to $0.2760 in pre-market trading. Abpro and Celltrion presented preclinical data for ABP-102/CT-P72, showcasing potential best-in-class HER2 X CD3 T-cell engager.</li>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) fell 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) fell 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

AGMH

AMPY

BBAI

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

HCAT

JZXN

OMEX

SPRB

XNET

Why Amplify Energy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

<ul>
<li>The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date.</li>
<li>In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo.</li>
<li>A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30.</li>
<li>A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30.</li>
<li>Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK and Japan that all have a label specifying near-complete stabilization (≥90%).</li>
<li>Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.</li>
<li>BridgeBio will receive royalties in a tiered structure beginning in the low-thirties percent on sales of Beyonttra in the UK</li>
</ul>

Biotech

News

Health Care

General

BBIO

The Medicines And Healthcare Products Regulatory Agency Has Approved BridgeBio Pharma's Acoramidis, Under The Brand Name Beyonttra, For Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy

China's National Development and Reform Commission (NDRC), the country's top economic planning agency, is downplaying the impact of President Donald Trump's tariffs and projecting strong growth despite mounting macroeconomic headwinds.
What Happened: On Monday, Zhao Chenxin, Vice Head of the NDRC, said he was &#8220;fully confident&#8221; that China would meet its target of 5% economic growth in 2025, despite mounting uncertainties and warnings of a sharp downturn from leading analysts, according to a Reuters report.
&#8220;No Matter how the international situation changes, we will anchor our development goals, maintain strategic focus, and concentrate on doing our own thing,&#8221; Zhao said.
This comes amid a particularly difficult period for the Chinese economy, which is already reeling from deflation and a prolonged property crisis. 
At the same time, Torsten Slok, the Chief Economist at Apollo Global Management, joined the growing chorus of experts and eminent intellectuals in recent weeks by predicting a &#8220;90% chance we&#8217;ll have a recession&#8221; if the tariffs remain at their current levels.
Speaking on the Economics Matters podcast on Friday, Slok said that small businesses that account for 80% of employment in the U.S. and 80% of the capital expenditure will be hit hard by the tariffs.
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/45033025/nvidia-faces-new-challenge-as-huawei-tests-powerful-ascend-910d-ai-chip-amid-us-sanctions-aiming-to-disrupt-high-end-market-report">Nvidia Faces New Challenge As Huawei Tests Powerful Ascend 910D AI Chip Amid US Sanctions, Aiming To Disrupt High-End Market: Report</a>
Why It Matters: Recession fears have continually edged higher throughout this past month, with economists, banks, and betting markets all pricing a <a href="https://benzinga.com/government/regulations/25/04/44801373/a-us-recession-in-2025-betting-odds-say-its-more-likely-than-not">high probability of a recession</a> this year.
There are, of course, others with a <a href="https://www.benzinga.com/25/04/44943850/chevron-ceo-sees-no-sign-of-recession-at-this-point-predicts-9-billion-in-free-cash-flow-by-2026">contrarian take on this</a>, such as the CEO of Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), who said last week that there were &#8220;no signs of a recession at this point.&#8221; 
Even the International Monetary Fund sees a slowdown in the global economy, but <a href="https://benzinga.com/markets/equities/25/04/44889521/recession-not-so-fast-says-imf-even-after-trump-tariff-chaos">stops short of forecasting a recession</a>, offering reassurance that the world can weather Washington&#8217;s tariff storm.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Apollo&#039;s Chief Economist, Torsten Slok, Estimates a 90 Percent Odds of Recession" width="500" height="281" src="https://www.youtube.com/embed/uuyWRT_B3n4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45032188/tom-lee-backs-scott-bessent-white-house-put-theory-as-nasdaq-flips-from-worst-april-start-since-great-depression-to-major-comeback">Tom Lee Backs Scott Bessent&#8217;s &#8216;White House Put&#8217; Theory As Nasdaq Flips From Worst April Start Since Great Depression To Major Comeback</a></li>
</ul>
Image Via Shutterstock

Government

Economics

Markets

As China Downplays Trump Tariffs With 5% Growth Target, Top Economist Warns Of '90% Chance Of A US Recession' Amid Trade War

<h3>Companies Reporting Before The Bell</h3>
• Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) is projected to report earnings for its Fiscal Year 2024. 
• Bright Scholar Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEDU#NYSE">BEDU</a>) is expected to report earnings for its second quarter. 
• Kandi Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) is estimated to report earnings for its fourth quarter. 
• SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) is projected to report quarterly loss at $0.46 per share on revenue of $6.48 million. 
• Provident Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROV#NASDAQ">PROV</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $9.86 million. 
• Toyo Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) is estimated to report earnings for its Fiscal Year 2024. 
• InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $77.57 million. 
• BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) is likely to report quarterly earnings at $0.76 per share on revenue of $263.57 million. 
• Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $556.31 million. 
• Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is projected to report quarterly earnings at $4.75 per share on revenue of $1.89 billion. 
• Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) is estimated to report quarterly earnings at $0.96 per share on revenue of $662.30 million. 
• Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $132.48 million. 
• Silicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>) is likely to report quarterly loss at $0.37 per share on revenue of $14.37 million. 
• Rithm Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPT#NYSE">RPT</a>) is projected to report earnings for its first quarter. 
• Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) is estimated to report earnings for its first quarter. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is likely to report quarterly earnings at $4.04 per share on revenue of $1.12 billion. 
• Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $16.16 million. 
• Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $27.99 million. 
• Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $3.85 billion. 
<h3>Companies Reporting After The Bell</h3>
• Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $169.00 million. 
• Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is projected to report quarterly loss at $0.25 per share on revenue of $116.40 million. 
• SunCar Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) is projected to report earnings for its Fiscal Year 2024. 
• EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $306.17 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is projected to report quarterly loss at $0.63 per share on revenue of $288.13 million. 
• Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) is likely to report quarterly earnings at $1.38 per share on revenue of $1.97 billion. 
• Firstsun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) is expected to report earnings for its first quarter. 
• CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) is estimated to report quarterly loss at $0.75 per share on revenue of $1.65 billion. 
• Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $1.02 billion. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is estimated to report quarterly earnings at $1.14 per share on revenue of $2.37 billion. 
• Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $127.51 million. 
• Financial Institutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $56.32 million. 
• Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is likely to report quarterly earnings at $1.68 per share on revenue of $6.12 billion. 
• Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) is estimated to report earnings for its first quarter. 
• Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) is expected to report quarterly earnings at $1.30 per share on revenue of $546.93 million. 
• Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) is estimated to report quarterly earnings at $1.14 per share on revenue of $276.83 million. 
• Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $162.83 million. 
• PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $243.68 million. 
• Cincinnati Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CINF#NASDAQ">CINF</a>) is likely to report quarterly loss at $0.52 per share on revenue of $2.71 billion. 
• F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) is projected to report quarterly earnings at $3.22 per share on revenue of $703.63 million. 
• NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is expected to report quarterly earnings at $2.60 per share on revenue of $2.83 billion. 
• Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $1.24 billion. 
• Gerdau (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGB#NYSE">GGB</a>) is estimated to report earnings for its first quarter. 
• Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is expected to report quarterly earnings at $2.29 per share on revenue of $758.46 million. 
• Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $7.31 billion. 
• Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $1.41 billion. 
• SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $160.54 million. 
• Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $-28 million. 
• Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $34.94 million. 
• Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $7.58 million. 
• Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $119.20 million. 
• SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is expected to report quarterly earnings at $2.32 per share on revenue of $661.98 million. 
• CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) is expected to report earnings for its first quarter. 
• CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $975.80 million. 
• UFP Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) is projected to report quarterly earnings at $1.57 per share on revenue of $1.61 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is projected to report quarterly earnings at $1.46 per share on revenue of $838.72 million. 
• Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is projected to report quarterly earnings at $1.77 per share on revenue of $544.94 million. 
• Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is projected to report quarterly earnings at $0.61 per share on revenue of $680.54 million. 
• Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) is projected to report quarterly loss at $0.10 per share on revenue of $884.92 million. 
• Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $141.29 million. 
• Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $334.61 million. 
• Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) is expected to report quarterly earnings at $4.38 per share on revenue of $4.16 billion. 
• COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $185.78 million. 
• Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) is projected to report quarterly earnings at $1.23 per share on revenue of $2.82 billion. 
• Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $863.31 million. 
• Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $1.28 billion. 
• NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $2.10 billion. 
• Northwest Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>) is estimated to report quarterly earnings at $0.24 per share on revenue of $142.16 million. 
• RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $28.98 million. 
• Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $53.04 million. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $44.21 million. 
• Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is likely to report earnings for its first quarter. 
• Alerus Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $66.19 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $561.40 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ABCB

ALRS

AMKR

ARLP

BEDU

BMRC

BYON

CDNS

CINF

EFSC

EZPW

FBRT

FFIV

FISI

Fomento Economico Mexicano S.A.B. De C.V.

FSBC

FSUN

GFAI

HLIT

INMD

KFRC

KNDI

MBIN

NTST

NWBI

NXPI

OPRA

PERF

PROV

RMBS

RVTY

SANM

SBAC

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SEVN

SILC

SPCB

TOYO

UCTT

UFPI

WELL

Earnings Scheduled For April 28, 2025

Analysts from Goldman Sachs have warned that the U.S. tariffs on Chinese imports could put up to 16 million jobs in China at risk, particularly in the manufacturing sector.
What Happened: The bank stated that persistently high U.S.-China tariffs and a significant drop in Chinese exports could put pressure on labor markets. The jobs under threat are primarily involved in the production of exports to the U.S., with nearly a quarter in the wholesale and retail sectors, <a href="https://www.scmp.com/economy/china-economy/article/3308140/us-tariffs-could-endanger-16-million-export-jobs-china-goldman-sachs">reported</a> the South China Morning Post.
"If high US-China tariffs were to persist and Chinese exports were to fall precipitously, labor markets would surely feel the pressure," stated the report
This year, the U.S. has levied tariffs of 145% on Chinese imports, pushing the effective tariff rate to around 156%. In retaliation, Beijing has imposed a 125% tariff on all U.S. goods, in addition to previous duties.
Goldman Sachs highlighted that communication equipment, apparel, and chemical products are more susceptible due to their significant share in US-bound exports from China. The bank also proposed that Chinese manufacturers could relocate production to third countries to circumvent high duties.
The report also noted that the U.S. removal of tariff exemptions for low-value package shipments is putting &#8217;employment pressure&#8217; on China's retail and wholesale sectors.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/04/45011721/intel-just-announced-q2-guidance-below-estimates-why-the-stock-is-tumbling" target="_blank" rel="noreferrer noopener">Intel Just Announced Q2 Guidance Below Estimates: Why The Stock Is Tumbling</a>
Why It Matters: Earlier this month,&nbsp;<a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">Goldman Sachs warned</a>&nbsp;about a sluggish economic recovery for China and deep labor market consequences. As per the bank, the tariffs could reduce Chinese real GDP by 2.6 percentage points — with a 2.2 percentage point impact hitting as soon as 2025.
The bank also predicted that the possibility of a U.S.-China decoupling could lead to a massive<a href="https://www.benzinga.com/25/04/44787496/goldman-sachs-warns-25-trillion-sell-off-in-the-extreme-event-of-us-china-decoupling-as-scott-bessent-says-everything-is-on-the-table"> $2.5 trillion </a>sell-off. In an extreme scenario, investors from both countries might be forced to divest their holdings of equities and debt instruments. 
Meanwhile, S&amp;P Global Ratings on Friday stated that Trump's tariff increases are expected to primarily affect China's coastal provinces, including Guangdong, Jiangsu, Shandong, and Zhejiang, along with Shanghai, a key port and financial hub.
That being said, a possible easing of trade tensions,&nbsp;China last week,<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> reportedly began </a>exempting&nbsp;some U.S. imports from high tariffs, including pharmaceutical imports and aerospace parts. Companies in China have been approached by officials to identify essential U.S. goods that are difficult to replace. Furthermore, the 24-member Politburo, led by President Xi Jinping, committed to stabilizing China's economy and employment, and called for support measures for those impacted by tariffs following a meeting last week.
The ADR of Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 0.8% to close at $120.28 on Friday, while that of PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) rose 0.72% to close at $104.01. Meanwhile, the ADR of NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) slid 0.05% to close at $105.86, as per <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">BenzingaPro</a>.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45027945/does-anybody-honestly-believe-manufacturing-is-coming-back-to-the-us-one-person-asked-says-youd-have-to-pay-" target="_blank" rel="noreferrer noopener">&#8216;Does Anybody Honestly Believe Manufacturing Is Coming Back To The US?&#8217; One Person Asked. Says, &#8216;You&#8217;d Have To Pay Americans $40–$50/Hr&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BABA

NTES

Citigourp Global Markets 2% Protected Notes Linked To The Djia

16 Million Jobs At Risk In China As US Tariffs Hammer Manufacturing And Retail Sectors, Goldman Sachs Warns

Pershing Square's Bill Ackman has hailed Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos-backed Slate Auto as the company recently revealed its $20,000 EV truck.
What Happened: Quoting a post that shared a Slate Auto commercial on social media platform X, Ackman hailed the company's modular approach to its vehicle on Saturday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is a going to be a big success. We all want more simplicity and flexibility in our lives. <a href="https://t.co/t7o7VYfBFM">https://t.co/t7o7VYfBFM</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1916123387669225910?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"This is a going to be a big success. We all want more simplicity and flexibility in our lives," Ackman shared in his post.
Why It Matters: Slate Auto has only one product on offer, which it calls the ‘Blank Slate.' In its base form, it is a two-seater EV pickup truck in grey with a 150-mile range, but customers can personalize the car in whatever way they want, including a 5-seater SUV.
The company says that with the federal EV credit, the <a href="https://www.benzinga.com/tech/25/04/45006513/jeff-bezos-backed-tesla-rival-unveils-20000-modular-ev-pickup-truck-with-customization-at-the-forefront">car could cost $20,000</a>, which is significantly cheaper than the likes of Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Cybertruck or Rivian Automotive Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) R1T.
While Slate Auto says the company aims to begin deliveries by 2026, the EV pickup truck has already garnered a lot of <a href="https://www.benzinga.com/tech/25/04/44784826/jeff-bezos-backed-slate-auto-to-take-on-elon-musks-tesla-rivian-with-budget-ev-pickup-report">buzz on social media</a> platforms like Reddit.&nbsp;
Interestingly, the release comes at a time when the domestic EV market in the U.S. is <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">experiencing a surge</a>, which Slate Auto could take advantage of given its product's competitive pricing.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="214" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1024x214.jpg" alt="" class="wp-image-890272" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1024x214.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-300x63.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-768x160.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1536x321.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN.jpg 1647w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Amazon scores Well on metrics like Momentum, Growth, and Quality, and has a Satisfactory score in the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/45032179/tesla-reportedly-developing-a-cheaper-model-y-e80-variant-with-fewer-features-in-china">Tesla Reportedly Developing A Cheaper Model Y &#8216;E80&#8217; Variant With Fewer Features In China</a></li>
</ul>
Image Via Slate Auto

Tech

AMZN

RIVN

TSLA

Bill Ackman Hails Jeff Bezos-Backed Tesla Rival Slate Auto, Says It Will Be 'A Big Success'

Huawei Technologies is reportedly preparing to test its most powerful artificial intelligence processor to date, with hopes of <a href="https://www.benzinga.com/25/03/44356270/huawei-develops-in-house-chips-to-counter-us-sanctions-and-leap-ahead-in-the-tech-war">replacing high-end chips</a> from U.S. giant Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), even as U.S. sanctions continue to stifle China&#8217;s semiconductor ambitions.
What Happened: Huawei has begun the testing phase of its new AI chip, the Ascend 910D, which is designed to rival Nvidia's flagship processors, <a href="https://www.wsj.com/tech/chinas-huawei-develops-new-ai-chip-seeking-to-match-nvidia-8166f606?mod=tech_lead_pos1">reported</a> the Wall Street Journal on Sunday, citing people familiar with the matter.
The chip will undergo a series of technical tests, with samples expected to be ready by late May. The Ascend 910D aims to surpass Nvidia's H100 chip, a popular choice for AI training tasks.
This move marks a significant step forward for Huawei's semiconductor division, which has faced substantial challenges due to <a href="http://v/">U.S. sanctions over</a> the past six years.
See Also:&nbsp;<a href="https://benzinga.com/25/04/45003790/mark-cuban-slams-amazon-for-ripping-off-american-sellers-as-tariffs-are-predicted-to-boost-ecommerce-brands-profi" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Amazon For ‘Ripping Off American Sellers' As Trump Tariffs Are Predicted To Boost Ecommerce Brands' Profits</a>
This year, Huawei plans to ship over 800,000 Ascend 910B and 910C chips. Customers include state-run telecoms and companies like ByteDance, the report noted, citing the sources. 
However, Huawei has been struggling to manufacture these chips on a large scale due to <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions">obstacles in its supply chain</a>. The company has been excluded from working with Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Its closest alternative, Semiconductor Manufacturing International, is also restricted from acquiring the latest chip-making technology.
Why It&#8217;s Important: Earlier this month, the U.S. government placed Nvidia's H20 chip—its most advanced processor available for sale in China without a license—on a list of semiconductors facing sales restrictions.
Nvidia revealed that this move would lead to a<a href="https://www.benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker"> $5.5 billion financial hit</a>.
On Sunday, Chamath Palihapitiya spoke about how <a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Huawei has effectively executed</a> a &#8220;low-end disruptor&#8221; strategy. This strategy focuses on creating products that match or exceed the quality of industry leaders, but at a more affordable price.
He highlighted several companies Huawei has already surpassed, including Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) and Nokia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>).
Previously, the SPAC king raised concerns that <a href="https://in.benzinga.com/markets/25/04/44891778/nvidia-not-acting-in-us-interests-says-chamath-palihapitiya-questions-how-alibaba-or-deepseek-are-one-step-ahead">Nvidia may not be prioritizing</a> the best interests of the U.S.
Benzinga Edge Stock Rankings places Nvidia&#8217;s growth score in the 94th percentile. Curious how other chip stocks compare? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to discover more</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/trading-ideas/movers/25/04/45029805/what-caused-sam-altman-founded-world-network-token-to-soar-57-in-a-week" target="_blank" rel="noreferrer noopener">What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week? What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Media

ERIC

MSFT

Nvidia Faces New Challenge As Huawei Tests Powerful Ascend 910D AI Chip Amid US Sanctions, Aiming To Disrupt High-End Market: Report

Global defense budgets reached unprecedented levels in 2024, driven by mounting conflicts and geopolitical strains. A new report from the Stockholm International Peace Research Institute (SIPRI) showcases a sensational increase in military spending across the globe.
What Happened: According <a href="https://www.sipri.org/media/press-release/2025/unprecedented-rise-global-military-expenditure-european-and-middle-east-spending-surges">to</a> SIPRI, military expenditure rose 9.4% to $2.72 trillion. This marks the most drastic annual increase since the Cold War concluded. All regions reported higher defense outlays, with Europe and the Middle East demonstrating particularly speedy growth. 
More than 100 nations enhanced their military budgets, often reallocating funds from other crucial sectors. U.S. military expenditure touched $997 billion, making up 66% of NATO&#8217;s total and 37% of global defense spending.
See Also: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-parents">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Why It Matters: Europe&#8217;s military expenditure, including Russia, soared 17%, moving past Cold War-era numbers. Russia&#8217;s defense budget alone rose by 38% to an approximate $149 billion, making up 7.1% of its Gross Domestic Product. 
Ukraine, despite major financial difficulties, increased military spending by 2.9% to $64.7 billion, with its defense budget now taking up all available tax revenue.
The report underscores rising concerns about the long-term impact of prioritizing military budgets over social and economic necessities. 
SIPRI warns that the trend could restructure societies for decades to come. In Europe, the ongoing war in Ukraine and ambiguity surrounding U.S. NATO support have prompted increased defense spending.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45030778/trump-running-american-economy-like-a-mafia-don-economist-craig-shapiro-draws-parallels-with-russias-president">Trump Running American Economy Like A &#8216;Mafia Don&#8217;: Economist Craig Shapiro Draws Parallels With Russia&#8217;s President</a></li>
</ul>
Image via Shutterstock

Global

Global Defense Budgets Surge To $2.7 Trillion As Europe And Middle East Lead Steepest Increase Since Cold War: Report

Buybacks

MIELY

Mitsubishi Electric Launches Share Buyback Program For 60M Shares Worth Up To JPY 100B

In a recent private event,&nbsp;Donald Trump Jr., son of the U.S. President, voiced his support for enhanced business cooperation with Eastern Europe.
What Happened: Trump Jr. underscored his close connections to the region during his address at the Trump Business Vision 2025 event organized by businessman Zoltán Aczél and Portfolio at Budapest, Hungary. He spotlighted his Czechoslovakian roots and language proficiency owing to his mother late Ivana Trump, and applauded the region&#8217;s dramatic evolution over the past five decades, <a href="https://www.portfolio.hu/en/economy/20250425/donald-trump-jr-we-want-to-do-a-lot-of-good-business-with-our-friendly-allies-757309">reported</a> Portfolio.
As the&nbsp;Executive Vice President of the&nbsp;Trump Organization, Trump Jr. praised Hungary&#8217;s robust political leadership, specifically Prime Minister Viktor Orbán. He expressed belief in the potential for successful collaboration between American and Hungarian businesses.
He is hopeful that the U.S.-Eastern Europe ties would generate a lot of business amid threats facing the U.S., Hungary and the Central and Eastern European region.
&#8220;I understand the threat that looms from so many places and it&#8217;s not the evil boogeyman of Russia, but likely China,&#8221; pointed out the U.S. President&#8217;s son. 
Trump Jr. recognized the necessity to diversify the U.S. economy&#8217;s dependencies, pointing out the high concentration of pharmaceutical production in China and advanced chip technology in Taiwan. He proposed that Eastern Europe, with its committed workforce and lower labor costs, could assume many activities currently outsourced to China.
&#8220;Pulling away from China is the first step, the dependence is too high,&#8221; stated Trump Jr.
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a>
Why It Matters: This comes at a time when the U.S. is experiencing strained relations with China. The ongoing trade war with China has led to a significant decrease in U.S. imports <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">from the</a> Asian nation, while China&#8217;s Ministry of Commerce has <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of ongoing trade discussions with the U.S.
Against this backdrop, analysts suggest there are concerns that China <a href="https://www.benzinga.com/news/global/25/04/44892820/xi-jinping-could-woo-europe-with-a-potential-china-deal-to-undercut-trumps-tariff-strategy-expert-warns">might leverage</a> the strained U.S.-EU relations to its benefit, leading Beijing to shift the majority exports to Europe.
Trump Jr.&#8217;s call for increased cooperation with Eastern Europe could be seen as a strategic move to diversify the U.S.&#8217;s economic dependencies amid these ongoing tensions. Despite not being a member of the Trump administration, Trump Jr. was hopeful about the renewal of the expired double tax treaty between the U.S. and Hungary, citing the strong relationship between his father, Donald Trump and Prime Minister Orbán.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45022796/this-is-not-really-how-i-pictured-my-life-at-30-air-force-vet-says-he-works-retail-for-18-an-hour-and-feels-" target="_blank" rel="noreferrer noopener">&#8216;This Is Not Really How I Pictured My Life At 30&#8217;—Air Force Vet Says He Works Retail For $18 An Hour And &#8216;Feels Like A Loser&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Jr. Leans On His Czech Roots To Boost US-Eastern Europe Ties While 'Pulling Away' From China: 'It's Not The Evil Boogeyman Of Russia, But Likely China'

Consolidated Financial Results Revenue: 5,521.7 billion yen (5% increase year-on-year) Operating profit: 391.8 billion yen (19% increase year-on-year) Profit before income taxes: 437.2 billion yen (20% increase year-on-year) Net profit attributable to Mitsubishi Electric Corp. stockholders: 324.0 billion yen (14% increase year-on-year)

Mitsubishi Electric's FY25 Revenue ¥5.521T, Up 5% YoY; Net Profit Attributable To Stockholders ¥324B, Up 14% YoY

CRWD

CrowdStrike Redefines Cybersecurity With Autonomous Charlotte AI Agentic Platform

SYNA

Synaptics Expands Veros Lineup With First Wi-Fi 7 SoCs Tailored For High-Performance, Low-Power IoT Applications

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ROP/earnings">opening bell on Monday, April 28.</a>
Analysts expect the Sarasota, Florida-based company to report quarterly earnings at $4.74 per share, up from $4.41 per share in the year-ago period. Roper Technologies projects to report quarterly revenue at $1.88 billion, compared to $1.68 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, Roper Technologies disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.
Roper Technologies shares fell 0.4% to close at $557.70 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/rop/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Stephen Tusa maintained a Neutral rating and cut the price target from $558 to $465 on April 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Brad Reback initiated coverage on the stock with a Buy rating and a price target of $685 on March 27, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Christopher Glynn maintained an Outperform rating and raised the price target from $630 to $640 on Jan. 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Raymond James analyst Brian Gesuale reiterated a Strong Buy rating and increased the price target from $620 to $655 on Jan. 31, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Julian Mitchell maintained an Underweight rating and cut the price target from $569 to $562 on Jan. 8, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ROP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png" alt="" class="wp-image-890254" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Roper Technologies Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients</li>
<li>TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients</li>
<li>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events</li>
<li>On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025</li>
<li>Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET</li>
</ul>

TARA

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ&#xAE; in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ&#xAE; among people in La Reunion. The three individuals who were hospitalized were over 80 years old and had pre-existing comorbidities3. These SAEs were reported through the pharmacovigilance system set up by the French health authorities, and causality has not been definitively established. The HAS maintains its current recommendation for IXCHIQ&#xAE; for people aged 18 to 64 years old as part of the ongoing vaccination campaign.

VALN

Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation

<ul>
<li>Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone</li>
<li>Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years</li>
<li>Results have been shared with global health authorities to support potential regulatory filings</li>
</ul>

Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

<ul>
<li>Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C</li>
<li>58.3% of patients showed durable complete responses by K-M at 24 months</li>
<li>97.3% of all treated patients remained free from progression to MIBC at 24 month</li>
<li>91.6% of responders remained cystectomy-free at 24 month</li>
<li>No Grade 3 or greater treatment-related adverse events or deaths reported</li>
<li>Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M</li>
<li>Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025</li>
</ul>

CGON

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

A man has become the first non-verbal, as well as only the third person ever, to receive a Neuralink Brain-Chip Interface (BCI) implant.
What Happened: Author Bradford G Smith suffers from ALS or Amyotrophic Lateral Sclerosis, a very rare nervous system disease that severely impacts motor functions. Smith released a video on the social media platform X to share the update on Sunday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am the 3rd person in the world to receive the <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. It is my primary communication. Ask me anything! I will answer at least all verified users! Thank you <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>! <a href="https://t.co/bxYO3SBfA2">pic.twitter.com/bxYO3SBfA2</a>
&mdash; Bradford G Smith (Brad) (@ALScyborg) <a href="https://twitter.com/ALScyborg/status/1916630186382291242?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Smith says that he uses the Neuralink implant to control the cursor on his laptop as well as Grok AI to create a clone of his own voice to speak. The video Smith shared was also edited by the BCI chip.
Why It Matters: The news comes as Elon Musk has touted his Neuralink BCI as technology that will help completely <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">blind people see again</a>, the billionaire shared.&nbsp;&nbsp;
Musk also reiterated that robots would <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">outperform human surgeons</a> in almost 5 years. He said Neuralink "had to use a robot for the brain-computer electrode insertion, as it was impossible for a human to achieve the required speed and precision."
Elsewhere, Neuralink is also eyeing an<a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report"> $8.5 billion pre-money valuation</a> in its latest round of funding as the company aims to raise over $500 million, in ongoing talks with investors.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Image Via Shutterstock

Man Battling ALS Becomes First Non-Verbal Patient To Receive Elon Musk's Neuralink Brain Implant

Press Releases

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Armata Pharmaceuticals Announces Structural Biology Publication

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Comments

Armata Pharmaceuticals

Notizie

Ultime notizie per Armata Pharmaceuticals (AMEX:ARMP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO